NRSN (NeuroSense Therapeutics) Ending Cash Position: $0.17 Mil (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.72
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Ending Cash Position?

NeuroSense Therapeutics NRSN +1.58% 31 Ending Cash Position is $0.17 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was $0.17 Mil.

NeuroSense Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 ($2.17 Mil) to Jun. 2025 ($0.67 Mil) and declined from Jun. 2025 ($0.67 Mil) to Dec. 2025 ($0.17 Mil).

NeuroSense Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($2.64 Mil) to Dec. 2024 ($3.38 Mil) but then declined from Dec. 2024 ($3.38 Mil) to Dec. 2025 ($0.17 Mil).

NeuroSense Therapeutics Ending Cash Position Related Terms

NeuroSense Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Ending Cash Position Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 11.06 3.54 2.64 3.38 0.17

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.45 1.21 2.17 0.67 0.17
NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

NeuroSense Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.378+-3.212
=0.17

NeuroSense Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.701+-0.535
=0.17

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.17 Mil mean?
NeuroSense Therapeutics (NRSN) has a Ending Cash Position of $0.17 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Ending Cash Position too high?
NeuroSense Therapeutics' current Ending Cash Position is $0.17 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Ending Cash Position compare to SER and PVCT?
NeuroSense Therapeutics' Ending Cash Position of $0.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Ending Cash Position is $0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Ending Cash Position of $0.17 Mil. The current Ending Cash Position is $0.17 Mil. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Ending Cash Position is $0.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price